| Literature DB >> 30740156 |
Hakim Bahlok Jebur1, Mirza Masroor2, Hafiz Ahmad3, Naushad Ahmad Khan4, Juheb Akther1, Dipu Bharali5, Vijay Kumar Singh6, Amit Verma7, Shahbaz Khan7, Vasiuddin Khan7, Rameez Hasan7, Deepti Bhatt7, Yamini Goyal7, Kapil Dev7.
Abstract
BACKGROUND: C-reactive protein (CRP) is an inflammatory marker associated with T2DM, obesity, insulin resistance, and cardiovascular disease. AIM: The present study evaluates the association of CRP +1059 G/C polymorphism of the CRP gene in 100 T2D cases and 100 healthy controls.Entities:
Keywords: Biochemical parameters; CRP gene polymorphism; Type 2 Diabetes
Year: 2018 PMID: 30740156 PMCID: PMC6352458 DOI: 10.3889/oamjms.2019.014
Source DB: PubMed Journal: Open Access Maced J Med Sci ISSN: 1857-9655
Distribution of selected characteristics among T2D patients and healthy controls
| Variables | T2D patients n (%) | Healthy controls n (%) |
|---|---|---|
| 100 (100%) | 100 (100%) | |
| Males | 62 (62%) | 64 (64%) |
| Females | 38 (38%) | 36 (36%) |
| ≤ 50 | 61 (%) | 66 (%) |
| > 50 | 39 (%) | 34 (%) |
| Mean age (years) | 49.82 | 47.89 |
| Yes | 63 (63%) | 28 (28%) |
| No | 37 (37%) | 72 (72%) |
| Yes | 20 (20%) | 5 (5%) |
| No | 80 (80%) | 95 (95%) |
| Yes | 58 (58%) | 30 (30%) |
| No | 42 (42%) | 70 (70%) |
| Yes | 49 (49%) | 26 (26%) |
| No | 51 (51%) | 74 (74%) |
Genotype distribution and allele frequencies of CRP (+1056G/C) gene among T2D patients and controls
| Variables | GG n(%) | GC n(%) | CC n(%) | p value | Allele frequency | |
|---|---|---|---|---|---|---|
| G allele | C allele | |||||
| 76 (76) | 16 (16) | 8 (8) | 0.001 | 0.84 | 0.16 | |
| 92 (92) | 8 (8) | 0 (0) | 0.96 | 0.04 | ||
Risk of T2D associated with CRP (+1056G/C) genotype
| Genotype | Healthy controls (n = 100) | T2D patients (n = 100) | OR (95% CI) |
|---|---|---|---|
| 92 (92%) | 76 (76%) | ||
| GC | 8 (8%) | 16 (16%) | 2.42 (0.98-5.96) |
| CC | 0 (0%) | 8 (8%) | 20.56 (1.16-362.1) |
| GC+CC | 8 (8%) | 24 (24%) | 3.63 (1.54-8.54) |
Risk of CRP genotype in T2D patients associated with different variables
| Genotype | HTN No (n = 37) | HTN Yes (63) | OR* (95% CI) |
|---|---|---|---|
| GC | 1.51 (0.47-4.79) | ||
| CC | 4.82 (0.56-41.20) | ||
| GC | 1.61 (0.44-5.80) | ||
| CC | 2.90 (0.61-13.72) | ||
| 35 | 41 | ||
| GC | 5 | 11 | 1.87 (0.59-5.92) |
| CC | 2 | 6 | 2.56 (0.48-13.51) |
| 32 | 44 | ||
| GC | 11 | 5 | 3.02 (0.95-9.56) |
| CC | 6 | 2 | 4.12 (0.78-21.79) |
Effect of different risk factor positive on serum markers level among T2D patients and healthy controls
| HTN history yes | In T2D | Healthy control | p-value |
|---|---|---|---|
| Cholesterol | 208.3 ± 43.49 | 210.2 ± 17.95 | 0.82 |
| TG | 182.8 ± 43.10 | 138 ± 23.67 | < 0.0001 |
| LDL | 138.9 ± 27.19 | 118.4 ± 15.54 | 0.0003 |
| VLDL | 34.62 ± 5.74 | 26.32 ± 3.78 | < 0.0001 |
| Serum uric acid | 5.51 ± 1.73 | 4.26 ± 0.59 | < 0.0001 |
| Bilirubin total | 0.83 ± 0.43 | 0.67 ± 0.20 | 0.23 |
| Fasting blood sugar | 174.8 ± 42.39 | 92.54 ± 11.66 | < 0.0001 |
| Postprandial blood sugar | 256.2 ± 54.99 | 127.1 ± 1.60 | < 0.0001 |
| Cholesterol | 207.6 ± 45.59 | 208 ± 27.16 | 0.98 |
| TG | 194.4 ± 47.36 | 174.8 ± 49.06 | 0.42 |
| LDL | 140 ± 27.69 | 109.2 ± 12.66 | 0.02 |
| VLDL | 33.80 ± 5.55 | 23.60 ± 4.27 | 0.0009 |
| Serum uric acid | 5.41 ± 1.51 | 4.02 ± 0.73 | 0.009 |
| Bilirubin total | 0.68 ± 0.33 | 0.78 ± 0.16 | 0.16 |
| Fasting blood sugar | 167.1 ± 31.61 | 93.0 ± 11.90 | < 0.0001 |
| Postprandial blood sugar | 251.5 ± 56.60 | 128.8 ± 10.03 | < 0.0001 |
| Cholesterol | 210.7 ± 45.08 | 201.6 ± 18.35 | 0.33 |
| TG | 191.1 ± 44.13 | 136.0 ± 14.46 | < 0.0001 |
| LDL | 139.1 ± 28 | 117.2 ± 14.20 | 0.0004 |
| VLDL | 34.22 ± 5.46 | 24.81 ± 4.36 | < 0.0001 |
| Serum uric acid | 5.75 ± 2.05 | 4.19 ± 0.87 | 0.0004 |
| Bilirubin total | 0.87 ± 0.44 | 0.68 ± 0.20 | 0.08 |
| Fasting blood sugar | 180.4 ± 46.93 | 93.42 | < 0.0001 |
| Postprandial blood sugar | 262.6 ± 55.92 | 123.3 ± 9.04 | < 0.0001 |
| Cholesterol | 208.2 ± 42.54 | 203.5 ± 20.04 | 0.56 |
| TG | 185.8 ± 48.01 | 136.3 ± 24.74 | < 0.0001 |
| LDL | 139.4 ± 29.59 | 113.1 ± 12.85 | < 0.0001 |
| VLDL | 35.09 ± 6.06 | 25.0 ± 4.08 | < 0.0001 |
| Serum uric acid | 5.44 ± 1.73 | 4.23 ± 0.92 | 0.0002 |
| Bilirubin total | 0.82 ± 0.39 | 0.66 ± 0.21 | 0.03 |
| Fasting blood sugar | 173.7 ± 42.02 | 92.0 ± 10.86 | < 0.0001 |
| Postprandial blood sugar | 261.1 ± 57.51 | 128.3 ± 8.92 | < 0.0001 |
Serum markers level of T2D patients and healthy controls
| Serum markers | T2D patients (Mean | Healthy controls (Mean | p-value |
|---|---|---|---|
| Cholesterol | 206.8 ± 43.02 | 205.2 ± 19.05 | 0.73 |
| TG | 183.3 ± 42.62 | 139.5 ± 24.92 | <0.0001 |
| LDL | 147.4 ± 28.77 | 113.3 ± 14.10 | <0.0001 |
| VLDL | 34.16 ± 5.62 | 25.32 ± 4.81 | <0.0001 |
| Serum uric acid | 5.44 ± 1.85 | 4.20 ± 0.74 | <0.0001 |
| Bilirubin total | 0.86 ± 0.44 | 0.64 ± 0.20 | 0.0003 |
| Fasting blood sugar | 171.1 ± 39.55 | 92.75 ± 10.88 | <0.0001 |
| Postprandial blood sugar | 257.7 ± 51.94 | 126.7 ± 9.58 | <0.0001 |